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Dopaminergic signaling within the basal ganglia has classically been thought to occur
within two distinct neuronal pathways; the direct striatonigral pathway which contains the
dopamine D1 receptor and the neuropeptides dynorphin (DYN) and substance P, and the
indirect striatopallidal pathway which expresses the dopamine D2 receptor and enkephalin
(ENK). A number of studies have also shown, however, that D1 and D2 receptors can co-
exist within the same medium spiny neuron and emerging evidence indicates that these
D1/D2-coexpressing neurons, which also express DYN and ENK, may comprise a third neu-
ronal pathway, with representation in both the striatonigral and striatopallidal projections of
the basal ganglia. Furthermore, within these coexpressing neurons it has been shown that
the dopamine D1 and D2 receptor can form a novel and pharmacologically distinct receptor
complex, the dopamine D1–D2 receptor heteromer, with unique signaling properties. This
is indicative of a functionally unique role for these neurons in brain. The aim of this review
is to discuss the evidence in support of a novel third pathway coexpressing the D1 and D2
receptor, to discuss the potential relevance of this pathway to basal ganglia signaling, and
to address its potential value, and that of the dopamine D1–D2 receptor heteromer, in the
search for new therapeutic strategies for disorders involving dopamine neurotransmission.
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The striatum, consisting of the ventrally located nucleus accum-
bens (NAc) and dorsal caudate putamen (CP), is the largest
component of a group of nuclei that comprise the basal ganglia
and associated mesolimbic system. The neuronal makeup of the
striatum consists predominantly (>90%) of medium spiny neu-
rons (MSNs), all of which express the inhibitory neurotransmitter
GABA. However MSNs also exist as different subtypes, exhibiting
discrete phenotypes that are characterized by their neuropeptide
and dopamine receptor content, and which are dependent upon
the neuronal pathways to which they are localized.
At least two major neuronal pathways in the basal ganglia have
been identiﬁed (Figure 1). The MSNs of the striatonigral pathway,
also called the “direct” pathway, project to substantia nigra retic-
ulata (SNr) and the internal segment of the globus pallidus (GPi;
analogous to rat entopeduncular nucleus,EPN).These neurons are
characterized by the expression of the neuropeptides dynorphin
(DYN) and substance P (SP), as well as the dopamine D1 receptor
(D1R). In contrast, the neurons of the striatopallidal “indirect”
pathway, projecting to the external segment of GP (GPe; analo-
gous to rat GP), express the neuropeptide enkephalin (ENK) and
the dopamine D2 receptor (D2R; Gerfen et al., 1990). These two
pathways work in concert to regulate thalamic output.
Traditional thinking has depicted the D1R and D2R as being
segregated to these discrete populations of striatalMSNs.However,
this idea has been becoming more difﬁcult to reconcile as increas-
ing evidence, both functional and neuroanatomical, indicates that
D1R and D2R can be coexpressed in a subpopulation of striatal
MSNs. Furthermore, the recent identiﬁcation of a novel dopamine
receptor complex in striatum, the dopamine D1–D2 receptor het-
eromer, also suggests that these coexpressing MSNs may have
unique functional characteristics that are distinct from those neu-
rons that exhibit dopamine receptor segregation. In this review we
describe the evidence showing D1R/D2R coexpression in a subset
of striatal MSNs and discuss their unique functional role in basal
ganglia and mesolimbic neurotransmission. We put forth that
these D1R/D2R-coexpressing MSNs represent a third functional
striatal pathway with signiﬁcant physiological relevance.
DOPAMINE D1R AND D2R ARE FUNCTIONALLY LINKED
Numerous reports have documented opposing effects of the Gs-
coupled D1R and Gi/o-coupled D2R on biological processes such
as adenylyl cyclase activity and cAMP formation (Hyttel, 1978;
Onali et al., 1985) and striatal acetylcholine release (DeBoer and
Abercrombie, 1996). However, it has also been demonstrated
that the concomitant activation of both D1R and D2R is essen-
tial to achieve certain other behavioral, biochemical, and elec-
trophysiological effects. For instance, past studies have shown
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FIGURE 1 | Classical model of the basal ganglia circuitry and
associated mesolimbic structures.The major projections of D1R-only
striatonigral and D2R-only striatopallidal neurons are depicted. In this model,
the D1R and D2R exhibit complete segregation. Inhibitory (dotted lines) and
excitatory (solid lines) pathways are shown. NAc, nucleus accumbens; CP,
caudate putamen; VP, ventral pallidum; GP, globus pallidus; EPN,
entopeduncular nucleus; STN, subthalamic nucleus; SNr, substantia nigra
reticulata; SNc, substantia nigra compacta; VTA, ventral tegmental area.
coactivation of the D1R and D2R as being necessary for max-
imal stereotyped and locomotor behavior (Walters et al., 1987;
White et al., 1988; DeBoer and Abercrombie, 1996), and more
recently it was reported that to evoke neural and behavioral phe-
notypes of cocaine sensitization, both D1R and D2R stimulation
is required (Capper-Loup et al., 2002). Similarly, at a cellular level,
combined administration of speciﬁc D1R and D2R agonists was
shown to potentiate immediate early gene expression (LaHoste
et al., 1993; Keefe and Gerfen, 1995). For example, while the sys-
temic administration of a dopamine D1R agonist induced the
expression of c-fos and zif268 in the dopamine-depleted stria-
tum, and a D2R agonist decreased zif268 expression, both ago-
nists together signiﬁcantly enhanced gene expression compared
to the D1R agonist alone (Keefe and Gerfen, 1995). Electro-
physiological evidence has also demonstrated that simultaneous
administration of D1R and D2R agonists could synergistically
inhibit the neuronal activity of NAc neurons (White and Wang,
1986; Hu et al., 1990), and restoration of long-term depression
of synaptic transmission following dopamine depletion occurred
by dopamine administration or coadministration of speciﬁc
D1R and D2R agonists but not by either selective agonist alone
(Calabresi et al., 1992).
Although the mechanisms for the D1R and D2R interaction
have been suggested to occur by receptor activation on discrete
neurons (Gerfen et al., 1995; LaHoste et al., 2000), or changes in
D2R-mediated cholinergic interneuron activity with subsequent
impact onD1R-expressing striatonigral neuronal transmission (Di
Chiara et al., 1994), in many studies the mechanisms were not
clearly understood. However, an interaction between the receptors
occurring within the same cell may have been involved in some
instances. For example, singleMSN–MSNconnections in neonatal
striatal cultures have been reported to exhibit modulation by both
D1R and D2R agonists (Geldwert et al., 2006) and the selective
activation of D1R or D2R in single striatal neurons differentially
modulated tetrodotoxin-sensitive sodium channels (Aizman et al.,
2000). The synergistic potentiation of the arachidonic acid release
by coadministration of D1R-selective and D2R-selective agonists
has also been observed in cells expressing both receptors (Piomelli
et al., 1991).
NEUROANATOMICAL EVIDENCE FOR D1R AND D2R
COLOCALIZATION
Given the functional linkage between D1R and D2R, neu-
roanatomical studies began to address the question of dopamine
receptor segregation and many of these studies have now shown,
both at the mRNA level and the protein level, that D1R and D2R
coexist in a fraction of striatal MSNs. In situ hybridization studies
examiningD1R andD2RmRNA in serial rat brain striatal sections
have shown overlap of D1R and D2R transcript expression in the
same neurons (Meador-Woodruff et al., 1991; Lester et al., 1993)
and double in situ hybridization has been used to report colo-
calization of D1R and D2R mRNA in some striatal neurons in
primate (Aubert et al., 2000). D1R/D2R mRNA coexistence was
also reported using single cell reverse transcription PCR in neona-
tal neurons (Surmeier et al., 1992, 1996) and immunolabeling has
been a widely used tool for visualizing striatal D1R/D2R coexpres-
sion at the protein level in both neonatal striatal cultures (Shetreat
et al., 1996; Wong et al., 1999; Aizman et al., 2000; Hasbi et al.,
2009) and in adult brain slices (Lee et al., 2004; Deng et al., 2006;
Hasbi et al., 2009; Perreault et al., 2010).
It had been noted that while neurons expressing solely mRNA
for the D1R or D2R were abundant in SP or ENK mRNA respec-
tively,neurons containingmRNA for bothD1RandD2Rexpressed
both SP and ENK mRNAs (Surmeier et al., 1996). Similarly, in
a recent study by Perreault et al. (2010), using highly validated
antibodies, it was shown that the D1R and D2R were expressed
exclusively in neurons containing both DYN and ENK. Although
a small minority of DYN/ENK neurons did not express D1R or
D2R, these ﬁndings indicated that SP/DYN–ENK coexpression
could be a useful marker for identifying neurons coexpressing
D1R and D2R. Interestingly, unlike the controversy surrounding
the localization of D1R and D2R, SP/DYN–ENK coexpression in
striatal neurons has been widely accepted, and overlap of SP/DYN
and ENK mRNA or protein in a proportion of striatal projection
neurons has been reported for a number of species (Penny et al.,
1986; Gerfen andYoung, 1988; Anderson and Reiner, 1990; Besson
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et al., 1990; Chen et al., 1998; Stefani et al., 1998; Reiner et al., 1999;
Vorobjev et al., 2000;Wang et al., 2006, 2007; Perreault et al., 2010).
Drd1a-EGFP AND Drd2-EGFP BAC TRANSGENIC MICE
In recent years, technological advances have provided novel
approaches for assessing dopamine receptor colocalization.
Enhanced green ﬂuorescent protein (EGFP)-tagged promoter ele-
ments of D1R and D2R in bacterial artiﬁcial chromosome (BAC)
transgenic mice is one such method, and has been used to quan-
tify the proportion of striatal neurons expressing the receptors
within the striatonigral and striatopallidal pathways (Valjent et al.,
2009). In an elegant study by Bertran-Gonzalez et al. (2008) it was
reported that while the majority of D1R and D2R were segregated
to these discrete pathways, an estimated 17% of NAc shell MSNs
exhibited receptor colocalization with ∼6% D1R/D2R coexpres-
sion in CP. Although there has been doubt as to the reliability of
BAC transgenic mice in providing an accurate representation of
dopamine receptor expression due to unlabeled neurons (Shuen
et al., 2008), another groupwas able to show that 100%of MSNs in
these mice expressed D1R, D2R or both (Matamales et al., 2009)
and that the proportion of neurons showing coexpression were
similar to that observed in the Bertran-Gonzalez study.
Fluorescence activated cell sorting (FACS), another relatively
novel method, is used for sorting a heterogeneous mixture of
biological cells and is based upon the ﬂuorescent characteris-
tics of each cell. Essentially, this method employs the ﬂuorescent
properties of the neurons in the BAC transgenic drd1a-EGFP or
drd2-EGFP mice to purify D1R-expressing and D2R-expressing
MSNs, and is often used to assess speciﬁc characteristics of these
two neuronal subtypes. The quality of the puriﬁcation process can
then be veriﬁed by assessing mRNA content of the each sample.
Using this process, it was recently shown that while puriﬁed D1R-
positive neurons from whole striatum displayed enrichment of
D1RmRNA,D2RmRNAwas also evident, albeit in small amounts
(Lobo et al., 2010). Similarly, D2R-positive neurons also displayed
evidence of minimal D1RmRNA being present. In addition, using
BAC transgenic mice with Cre recombinase being driven by the
D1R or D2R promoters, and using double immunoﬂuoresence to
stain for Cre and ENK, this group also showed that a fraction of
striatal D1R-expressing neurons were also positive for ENK.
FUNCTIONAL RELEVANCE OF D1R/D2R-COEXPRESSING
NEURONS
Although the existence of D1R- and D2R-coexpressing MSNs is
now generally accepted, little is yet known about the functional
relevance of these neurons, most likely as a result of the method-
ological difﬁculties attempting to isolate them. However, it has
been shown that while all MSNs express mRNA for the GluA1
and GluA2 subunits of the AMPA receptor (Chen et al., 1998;
Stefani et al., 1998; Vorobjev et al., 2000), only SP/ENK neurons
preferentially express mRNA for GluA3 (Stefani et al., 1998) a
ﬁnding which the authors posited as being suggestive of distinc-
tive postsynaptic glutamatergic mechanisms in the neurons. A
role in neurotransmission is supported by evidence document-
ing that striatal projection neurons coexpressing D1R and D2R or
SP and ENK terminate in a number of regions including GP and
EPN (GPi), as well as substantia nigra and ventral tegmental area
(Deng et al., 2006; Wang et al., 2006, 2007), two regions rich in
dopamine cell bodies. In addition, a region-speciﬁc distribution
of D1R/D2R-DYN/ENK neurons throughout the rat basal gan-
glia and mesolimbic pathway has been reported, being present in
NAc (Figure 2) and CP, as well as GP and ventral pallidum and
EPN (Perreault et al., 2010). Speciﬁcally, it was estimated that the
fraction of D1R-expressing neurons also expressing the D2R in
NAc core and shell was ∼25% and ∼35% respectively, whereas in
CP the percentage was much lower being only ∼7%. In GP and
VP, while the total number of D1R neurons was quite low com-
pared to other regions, a high percentage of these neurons (∼60%
and∼30%) also contained D2R. Similarly, in EPN the fraction of
D1R containing neurons also expressing the D2R was relatively
high (∼50%).
In basal ganglia, the coexpression of D1R and D2R has been
shown to occur both within neuronal cell bodies and selectively
at presynaptic, but not postsynaptic terminals, as evidenced by
D1R and D2R coexpression with the presynaptic marker synapto-
physin, but not the postsynaptic marker PSD-95 (Perreault et al.,
2010). Presynaptic colocalization of D1R and D2R on a fraction
of varicosities has also been reported in neonatal striatal cultures
(Wong et al., 1999; Geldwert et al., 2006; Mizuno et al., 2007)
and electrophysiology studies have demonstrated that presynaptic
dopamine receptors on MSN terminals could modulate GABAer-
gic inhibitory postsynaptic currents (IPSCs; Delgado et al., 2000;
Guzman et al., 2003; Geldwert et al., 2006). Interestingly, in one
of these studies it was shown that while the D2R agonist quinpi-
role predominantly mediated inhibition of autaptic connections
in MSNs, the D1R agonist SKF 38393 mediated either inhibition
or facilitation (Geldwert et al., 2006). Although the authors did
not directly address the seemingly discrepant effects of the D1R
agonist on GABA transmission, it has been shown that SKF 38393
activates two biologically different signaling pathways, the cAMP
pathway and phospholipase C (PLC)-phosphoinositide (PI) path-
way (Undie and Friedman, 1990; Undie et al., 1994). Although
it has been suggested that these two pathways are linked directly
to D1R (Undie et al., 1994), it is now known that in MSNs that
coexpress D1R and D2R, the receptors can form a heteromeric
complex, the dopamine D1–D2 receptor heteromer, and it is this
complex that directly activates the PLC-PI pathway (Lee et al.,
2004; Rashid et al., 2007).
THE DOPAMINE D1–D2 RECEPTOR HETEROMER
Dopamine receptors exist as receptor homomers and can addi-
tionally form heteromeric receptor complexes that often exhibit
pharmacological and cell signaling properties distinct from their
constituent receptors (Lee et al., 2004; Rashid et al., 2007; Hasbi
et al., 2009; So et al., 2009; Verma et al., 2010). A physical inter-
action between the D1R and D2R was ﬁrst shown by coimmuno-
precipitation from rat and human striatum (Lee et al., 2004), and
was the ﬁrst evidence of a dopamine heteromeric receptor com-
plex in brain. These ﬁndings were later conﬁrmed by ﬂuorescence
resonance energy transfer (FRET) a tool commonly used for the
identiﬁcation of receptor oligomers. Although ﬁrst performed in
cells (So et al., 2005; Dziedzicka-Wasylewska et al., 2006), quan-
titative FRET in situ has now been utilized to verify the presence
of dopamine D1–D2 receptor heteromers in neonatal cultured rat
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FIGURE 2 |The dopamine D1 and D2 receptor are colocalized with
dynorphin and enkephalin in rat nucleus accumbens shell. (A,B) Confocal
images showing D1R and D2R colocalization with dynorphin (DYN) or
enkephalin (ENK; white arrows). The D1R was also expressed individually with
DYN (yellow arrows). (C,D) Neurons coexpressing DYN and ENK also
expressed the D1R or the D2R (white arrows).
striatal neurons (Hasbi et al., 2009). Similarly, this method has
now been employed to show, in vivo, that in adult rat NAc, CP
(Hasbi et al., 2009; Perreault et al., 2010) and GP (Figure 3) the
D1R and D2R existed in close <50–100Å proximity indicative
of D1–D2 receptor heteromerization. However, the propensity
for striatal neurons to exhibit D1–D2 heteromers was region-
dependent, with the majority (>90%) of D1R/D2R-coexpressing
neuronal cell bodies in NAc core and shell showing robust D1–
D2 heteromer formation, but only ∼25% of D1R/D2R neurons
expressing the D1–D2 heteromer in CP (Perreault et al., 2010).
This suggests that D1R and D2R can coexist as homomers in the
same cell without forming heteromers. It was also shown in the
neuropil of both NAc and CP the presence of D1–D2 heteromers
at presynaptic terminals, a ﬁnding that suggests a possible involve-
ment of synaptic D1–D2 receptor heteromer in GABA release in
both regions.
The role of the D1–D2 heteromer in vivo is just beginning to be
elucidated, however several lines of evidence have emerged impli-
cating the complex as a potential therapeutic target in disorders
involving elevated dopamine transmission, such as schizophrenia
and drug addiction. Speciﬁcally, it has been postulated that abnor-
mal regulation of calcium signaling may constitute the central
dysfunction that is responsible for generating the psychopathol-
ogy of schizophrenia (Lidow, 2003). Although the D1R and D2R
have not been shown individually to be directly coupled to calcium
signaling, coactivation of both receptors within the dopamine
D1–D2 receptor heteromer by concurrent administration of D1R
and D2R agonists, or the selective D1–D2 heteromer agonist SKF
83959, resulted in a novel Gq-PLC-linked increase in intracellular
calcium release (Lee et al., 2004; Rashid et al., 2007). In addi-
tion, dopamine D1–D2 heteromer activation by SKF 83959 also
induced striatal calcium calmodulin kinase IIα (CaMKIIα) phos-
phorylation (Rashid et al., 2007; Ng et al., 2010) and brain-derived
neurotrophic factor (BDNF) expression (Hasbi et al., 2009) two
proteins that have been linked to schizophrenia (Weickert et al.,
2003; Issa et al., 2010; Jindal et al., 2010; Novak and Seeman, 2010;
Wong et al., 2010; Carlino et al., 2011). Finally, of particular rele-
vance, an upregulation of striatal D1–D2 heteromeric activity was
seen following repeated amphetamine treatment in rats and in
human GP of patients with schizophrenia (Perreault et al., 2010).
Given that amphetamine sensitization is often employed as an
animal model for schizophrenia (Featherstone et al., 2007), but
no common biochemical marker linking the two has previously
been documented, it was inferred that the sensitized state of the
D1–D2 heteromer may provide the ﬁrst neuropharmacological
correlate between increased dopamine neurotransmission and its
functional consequence. As antipsychotics invariably also target
the D1–D2 heteromer, these ﬁndings strongly suggest that further
research examining the D1–D2 receptor heteromer as a potential
drug target in schizophrenia is warranted.
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FIGURE 3 | Dopamine D1 and D2 receptors form D1–D2 receptor
heteromers in rat globus pallidus. Fluorescence resonance energy
transfer (FRET), using Alexa 488 and Alexa 350 was used to identify
interactions between endogenous D1R and D2R in neurons of rat
globus pallidus. An interaction between the D1R and D2R was evident,
with a relatively high mean FRET Efﬁciency (efﬁciency of energy transfer
between the donor and acceptor ﬂuorophores) of ∼22%.The receptor
antibody-linked ﬂuorophores were calculated to be in close proximity with a
relative distance of 5–7 nm (50–70Å) indicative of D1–D2 receptor heteromer
formation.
In addition to an involvement in schizophrenia, CaMKII and
BDNF have also been shown to play a major role in cocaine addic-
tion (Anderson et al., 2008; Lobo et al., 2010; McGinty et al., 2010;
Wang et al., 2010). In one particularly compelling study, it was
shown that cocaine reinstatement in rats depended upon an inter-
action between NAc dopamine and glutamate systems that was
mediated by CaMKII (Anderson et al., 2008). More speciﬁcally,
cocaine reinstatement increased activation of NAc shell CaMKII,
which subsequently led to the phosphorylation of the GluA1 sub-
unit of the AMPA receptor at Ser831, and increased cell-surface
expression of GluA1-containing AMPA receptors. Interestingly, in
contrast to the effects of acute selective activation of the D1–D2
heteromer in NAc, more prolonged selective activation has been
reported to reduce total CaMKII levels in this region and addition-
ally reduce phosphorylation of GluA1 at Ser831 (Perreault et al.,
2010), a ﬁnding effectively linking the D1–D2 heteromer to the
reward pathways of the brain.
A CAUTIONARY NOTE ON THE USE OF DOPAMINE RECEPTOR
AGONISTS
It is now known that the agonist SKF 83959 directly activates cal-
cium signaling via the dopamine D1–D2 receptor heteromer, but
does not activate the D1R cAMP pathway or the Gi-coupled D2R
(Rashid et al., 2007). Therefore ﬁndings from studies assessing
the effects of SKF 83959 would not likely have been derived from
functional interactions between D1R or D2R homomers within
the same neuron, or between the D1R-expressing striatonigral and
D2R-expressing striatopallidal populations of MSNs.However, for
many years it was believed that the effects of the agonist SKF 83959
were mediated through its actions solely at the D1R. Reports had
demonstrated that SKF 83959 had a substantial afﬁnity for the
D1R (Andringa et al., 1999; Neumeyer et al., 2003), however the
physiological actions of SKF 83959 at the D1R were the subject
of much debate as the drug exhibited antagonistic properties on
adenylyl cyclase activity (Arnt et al., 1992; Andringa et al., 1999;
Jin et al., 2003) yet mimicked certain behavioral characteristics
of D1R agonism such as grooming or the induction of circling
behavior (Deveney and Waddington, 1995; Gnanalingham et al.,
1995; Waddington et al., 1995; Zhen et al., 2005; Perreault et al.,
2010). However, SKF 83959 was also linked to PLC activation and
PI hydrolysis in brain (Panchalingam and Undie, 2001; Jin et al.,
2003; Zhen et al., 2005; Rashid et al., 2007), a pathway that had
also been observed to be induced with a number of other D1R
agonists in brain tissue (Undie et al., 1994; Desai et al., 2005) but,
interestingly, not in cells expressing only the D1R (Lin et al., 1995).
Given the ability of D1R agonists to directly induce PI hydroly-
sis in brain, but not in cells expressing solely the D1R, this suggests
that D1R agonists that stimulate this pathway do so through ago-
nist activity at the D1–D2 receptor heteromer. For example, the
D1R agonists SKF 81297 and SKF 38393 are still often employed
as “selective” D1R agonists, despite evidence demonstrating their
ability to induce behavioral and neurochemical effects character-
istic of dopamine D1–D2 heteromer activation, such as grooming
and activation of PLC leading to intracellular calcium release
(Molloy andWaddington, 1987;Undie and Friedman, 1990;Undie
et al., 1994; Rashid et al., 2007). Furthermore, the D5 receptor
has also been shown to induce a calcium signal through PLC
activation or extracellular calcium inﬂux (So et al., 2009), fur-
ther confounding the pharmacological proﬁle of these agonists.
As such, the interpretation of both past and future results should
take into account that activation of individual dopamine receptors
by these compounds most likely occurs in tandem with D1–D2
receptor heteromer activation on the physiologically relevant sub-
set neurons coexpressing both the D1R and D2R. The appropriate
selection of dopaminergic drugs is therefore essential to effec-
tively isolate the speciﬁc complex, or signaling pathway, under
investigation.
CONCLUDING REMARKS
For themost part, studies agree that theD1R andD2R are predom-
inantly segregated to discrete populations of MSNs in striatum
and, additionally, that functional cross-talk between the D1R and
D2R is critical in mediating some of the physiological effects of
dopamine, such as the synergistic effects of D1R/D2R activation
on immediate early gene expression. However, there is also an
abundance of evidence showing that a proportion of MSNs in
striatum coexpresses the D1R and D2R, and the physiological
importance of these neurons is now beginning to become appar-
ent. Speciﬁcally, unlike D1R-only and D2R-only striatal MSNs,
D1R/D2R-coexpressing striatal projection neurons have been
reported to terminate in regions within both the striatonigral and
striatopallidal pathways, as well as regions containing dopamine
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neuronal cell bodies. These ﬁndings, as well as the demonstration
of D1R/D2R coexpression at presynaptic terminals, indicate that
receptor coexpression may have a unique physiological function
at a local level, via MSN–MSN synaptic connections, as well as
distal effects through their efferent projections (Figure 4). This
would likely contribute to the regulation of thalamic neurotrans-
mission, perhaps with the purpose of maintaining homeostatic
balance between the direct and indirect pathways. It is possible
that this may occur, at least in part, through the regulation of post-
synaptic glutamate transmission in the basal ganglia (Stefani et al.,
1998), as these neurons exhibit a unique expression phenotype of
the AMPA GluA subunits. In addition, these D1R/D2R MSNs also
express the dopamine D1–D2 receptor heteromer, a novel recep-
tor complex that links dopamine receptor activation directly to
calcium signaling and BDNF production in vivo. Together, the evi-
dence indicates that MSNs coexpressing the D1R and D2R in the
basal ganglia embody a physiologically relevant, and functionally
active, subset of neurons.We propose that D1R/D2R-coexpressing
MSNs represent a third major dopamine receptor neuronal path-
way, in addition to the striatonigral and striatopallidal pathways,
with the potential to provide a novel approach to drug discovery
in basal ganglia disorders.
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FIGURE 4 | Model of D1 and D2 receptor-coexpressing projections in
the basal ganglia circuitry. Previously reported (solid lines; Deng et al.,
2006; Wang et al., 2006, 2007) projection sites of D1R/D2R or
SP/ENK-coexpressing neurons and putative projections of
D1R/D2R-DYN/ENK neurons (dashed lines), based on the reported regional
distribution of neuronal cell bodies and presynaptic D1R and D2R
colocalization (Perreault et al., 2010).
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